Please use this identifier to cite or link to this item:
http://hdl.handle.net/11054/2342
Title: | Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance. |
Author: | Barraclough, A. England, J. Villa, D. Hapgood, G. Conn, J. Doo, N. Gilbertson, M. Shaw, B. Bishton, M. Saeed, M. Lee, H. Fleming, K. Tam, C. Douglas, G. Cheah, C. Ng, Z. Rolfe, T. Mills, A. Hamad, N. Cashman, H. Gleeson, M. Narayana, M. Hawkes, E. Ratnasingam, S. Abeyakoon, C. Chong, Geoff Wai, S. Ku, M. |
Issue Date: | 2023 |
Publication Title: | Haematologica |
Volume: | 108 |
Issue: | 9 |
Start Page: | 2444 |
End Page: | 2453 |
Abstract: | Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between 'lowgrade' (Grade 1, 2 and 3A FL) and diffuse large B-cell lymphoma (DLBCL) appearing to share features with each. Clinical characteristics and outcomes are poorly understood due to lack of adequate representation in prospective trials and large-scale analyses. We analyzed 157 G3BFL cases from 18 international centers, and two comparator groups; G3AFL (n=302) and DLBCL (n=548). Composite histology with DLBCL or low-grade FL occurred in approximately half of the G3BFL cases. With a median of 5 years follow-up, the overall survival and progression-free survival of G3BFL patients was better than that of DLBCL patients (P<0.001 and P<0.001, respectively); however, G3BFL patients were younger (P<0.001) with better performance status (P<0.001), less extranodal disease (P<0.001) and more frequently had normal lactate dehydrogenase (P<0.001) at baseline. The overall and progression-free survival of patients with G3BFL and G3AFL were similar (P=0.83 and P=0.80, respectively). After frontline immunochemotherapy, 24% of G3BFL relapsed; relapse rates were 63% in the DLBCL cohort and 19% in the low-grade FL cohort. Eight percent of relapses occurred beyond 5 years. In this G3BFL cohort, the revised International Prognostic Index successfully delineated risk groups, but the Follicular Lymphoma International Prognostic Index did not. We conclude that patients with immunochemotherapy-treated G3BFL have similar survival outcomes to those with G3AFL, yet a favorable baseline profile and distinctly superior prognosis compared to patients with DLBCL. |
URI: | http://hdl.handle.net/11054/2342 |
DOI: | https://doi.org/10.3324/haematol.2022.281375 |
Internal ID Number: | 02332 |
Health Subject: | LYMPHOMA |
Type: | Journal Article Article |
Appears in Collections: | Research Output |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.